ClinicalTrials.gg
Active, not recruitingNCT04544449FENtrepidUpdated Sep 17, 2026

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

A Phase 3 interventional study of Fenebrutinib and Ocrelizumab in Multiple Sclerosis, Primary Progressive, sponsored by Hoffmann-La Roche. Active, not recruiting at 190 sites in 28 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
985
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Multiple Sclerosis, Chronic Progressive by Hoffmann-La Roche — 2 open to participants now, 8 under way, 4 of them phase 3. Multiple Sclerosis, Chronic Progressive · Hoffmann-La Roche.

Enrollment
2nd of 12
985 · median 400
Started
2020
with 1 other
Phase 3
7 of 12
none open now
Registered
6th of 12
by date

Among the 12 studies in Multiple Sclerosis, Chronic Progressive by Hoffmann-La Roche, this one is the 2nd largest by enrollment, is one of 2 that started in 2020, is one of 7 in phase 3, and was the 6th registered.

Multiple Sclerosis, Chronic Progressive

245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.

Browse Multiple Sclerosis, Chronic Progressive studies →

Open to participants now

2 of the 12 studies in Multiple Sclerosis, Chronic Progressive by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 39 Multiple Sclerosis, Chronic Progressive studies recruiting now, 7 (18%) set no upper age limit and 26 (67%) stop at 75 or younger; none take children under 18; 6 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Multiple Sclerosis, Chronic Progressive by Hoffmann-La Roche, or all of them as a file.
02

Study summary

A study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study.

03

Conditions studied

  • Multiple Sclerosis, Primary Progressive
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For sites in Germany and Italy only, enrollment is restricted to participants aged 46-65 years
  • A diagnosis of PPMS in accordance to the revised 2017 McDonald Criteria (Thompson et al. 2018).
  • Disability progression in the 12 months prior to screening.
  • Expanded Disability Status Scale (EDSS) score from 3.0 to 6.5 inclusive at screening.
  • Pyramidal functional subscore >=2 at screening.
  • For participants currently receiving proton pump inhibitors (PPIs), H2-receptor antagonists (H2RAs), symptomatic treatment for MS (e.g. fampridine, cannabis) and/or physiotherapy: treatment at a stable dose during the screening period prior to the initiation of study treatment and plans to remain at a stable dose for the duration of study treatment.
  • Neurologically stable for at least 30 days prior to randomization and baseline assessments.
  • Ability to complete the 9-Hole Peg Test (9-HPT) for each hand in \<240 seconds.
  • Ability to perform Timed 25-Foot Walk Test (T25FWT) in \<150 seconds.
  • For female participants of : agreement to remain abstinent (refrain from heterosexual intercourse) or use measures, and refrain from donating eggs.
  • For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating sperm.

OLE Inclusion Criteria:

  • Completed the Double-Blind Treatment (DBT) phase of the study (remaining on study treatment; no other Disease-Modifying Therapy (DMT) administered) and who, in the opinion of the investigator, may benefit from treatment with fenebrutinib.
  • For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating eggs.
  • For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating sperm.

Exclusion criteria

Exclusion Criteria:

  • For participants enrolled in Germany and in Italy only: Presence of gadolinium-enhancing lesions on T1-weighted MRI (T1Gd +) lesion on the screening MRI
  • Any known or suspected active infection (excluding onychomycosis) at screening, including but not limited to a positive screening test for and C, an active or latent or inadequately treated infection with tuberculosis (TB), a confirmed or suspected progressive multifocal leukoencephalopathy (PML).
  • Participants with a previous history of a serious Infusion-Related Reaction (IRR) ( [CTCAE] Grade >= 4) and/or any reaction to ocrelizumab.
  • History of cancer including hematologic and solid tumors within 10 years of screening. Exceptions: Basal/squamous cell carcinoma of skin cured by excision. In situ carcinoma of the cervix successfully treated by curative therapy >1 year prior to screening.
  • Known presence of other neurological disorders, that could interfere with the diagnosis of MS or assessments of efficacy or safety during the study, cardiovascular, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic or gastrointestinal disease.
  • Presence of cirrhosis ( Class A, B, or C)
  • Chronic liver disease unless considered stable for >6 months
  • Acute liver disease
  • Any concomitant disease that may require chronic treatment with systemic , or specific medication that could impact the primary evaluation of the study.
  • History of alcohol or other drug abuse within 12 months prior to screening.
  • Female participants who are pregnant or breastfeeding or intending to become pregnant during the study or 6 or 12 months (as applicable from the local label for ocrelizumab) after final dose of study drug.
  • Male participants intending to father a child during the study or for 28 days after final dose of study drug.
  • Lack of peripheral venous access.
  • Any previous treatment with immunomodulatory or immunosuppressive medication without an appropriate .
  • Receipt of a live or within 6 weeks prior to randomization.
  • Immunocompromised state, history of primary or secondary (non-drug related) immunodeficiency, or history of transplantation or antirejection therapy
  • Known bleeding diathesis, anemia, or history of hospitalization or transfusion for gastrointestinal (GI) bleed
  • Any previous treatment with cladribine, mitoxantrone, daclizumab, alemtuzumab, or cyclophosphamide

OLE Exclusion Criteria:

  • Chronic liver disease unless considered stable for > 6 months
  • Acute liver disease
  • Cirrhosis (Child-pugh Class A, B or C)
  • Gilbert's syndrome
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
985 participants (actual)

Study arms

  • Experimental
    Fenebrutinib

    Participants will receive oral fenebrutinib and IV ocrelizumab-matching placebo.

    Drug: Fenebrutinib · Drug: Placebo matched to ocrelizumab

  • Active comparator
    Ocrelizumab

    Participants will receive IV ocrelizumab and oral fenebrutinib-matching placebo.

    Drug: Ocrelizumab · Drug: Placebo matched to fenebrutinib

Interventions

  • Participants will receive fenebrutinib.

  • Participants will receive ocrelizumab.

  • DrugPlacebo matched to ocrelizumab

    Participants will receive ocrelizumab-matching placebo.

  • DrugPlacebo matched to fenebrutinib

    Participants will receive fenebrutinib-matching placebo

06

What researchers measure

Primary outcomes

  1. Time to Onset of Composite 12-Week Confirmed Disability Progression (cCDP12)

    Time frame: Minimum of 120 weeks

Secondary outcomes

  1. Time to Onset of Composite 24-week CDP (cCDP24)

    Time frame: Minimum of 120 weeks

  2. Time to Onset of 12-week CDP (CDP12)

    Time frame: Minimum of 120 weeks

  3. Time to Onset of 24-week CDP (CDP24)

    Time frame: Minimum of 120 weeks

  4. Percentage Change in Total Brain Volume Assessed by Magnetic Resonance Imaging (MRI)

    Time frame: From Week 24 to Week 120

  5. Percent Change from Screening in Blood Neurofilament Light Chain (NfL) Levels

    Time frame: Up to Week 120

  6. Change from Baseline in Participant-Reported Physical Impacts of Multiple Sclerosis (MS) Measured by the Multiple Sclerosis Impact Scale, 29-Item [MSIS-29] Physical Scale

    Time frame: Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108 and 120

  7. Time to Onset of 12-week Confirmed 4-point Worsening in Symbol Digit Modality Test (SDMT) Score

    Time frame: Minimum of 120 weeks

  8. Percentage of Participants with Adverse Events (AEs)

    Time frame: Up to 4.7 years

  9. Plasma Concentrations of Fenebrutinib at Specified Timepoints

    Time frame: Up to 4.7 years

07

Study locations

190 sites

Showing the first 100 of 190 sites across 28 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Sep 2025, 58 months.

Of 20 phase 3 interventional studies under Multiple Sclerosis, Chronic Progressive, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 83. This study's 58 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2020
First posted
Sep 10, 2020
StartActual
Oct 26, 2020
Primary completionActual
Sep 17, 2025
CompletionEst.
Jul 21, 2027
Results delay requested
Sep 2, 2026
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04544449
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 10, 2020
Start date
Oct 26, 2020
Primary completion
Sep 17, 2025
Completion
Jul 21, 2027 (estimated)
Last update
Sep 17, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fenebrutinib

Start the discussion